EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Serum levels of prostate specific antigen, free PSA, [−2]proPSA, fPSA/tPSA ratio, Prostate Health Index, and glycosylation patterns of free PSA in patients with benign prostatic hyperplasia pharmacotherapy

Michal Jirásko iD, Roman Viták iD, Ladislav Pecen, Andrea Pinkeová iD, Jan Tkáč, Tomáš Bertók, Natalie Bergman, Radek Kučera

The Prostate · 2025

DOI: 10.1002/pros.24801 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Prostate, 2025. Verfasst von Michal Jirásko und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology and Toxicology, Faculty of Medicine in Pilsen, Charles University, Pilsen, 323 00, Czech Republic. Hauptthemen laut MEDLINE: Prostate-Specific Antigen, Prostatic Hyperplasia, Muscarinic Antagonists. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: "COOPERATIO" Program, research area Pharmaceutical Sciences, project BBMRI. cz, reg. no. LM2023033, Faculty Hospital in Pilsen-FNPl, 00669806.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The medication used to treat benign prostate hyperplasia (BPH), a common condition in men over 50 years of age, can alter the levels of biomarkers used in prostate cancer detection. Commonly used medications for BPH include alpha‐blockers, 5‐alpha reductase inhibitors (5‐ARIs), and muscarinic antagonists. We studied the impact of these drugs on total prostate‐specific antigen (tPSA), free PSA (fPSA), [−2]proPSA, fPSA/tPSA ratio, and the Prostate Health Index (PHI), as well as novel potential biomarkers in the form of glycan composition of fPSA. Patients and Methods Serum samples were collected from 564 males with BPH, with a mean age of 68.5 years. The samples were used to measure levels of tPSA, fPSA, and [−2]proPSA. The fPSA/tPSA and PHI were then calculated. The glycan composition of fPSA was analyzed using lectin‐based glycoprofiling. Pharmacotherapy data was collected from the patients' medical records.

Results

Alpha‐blocker monotherapy was associated with higher fPSA and fPSA/tPSA ratio, and decreased PHI. Levels of tPSA were not impacted. Alpha‐blocker and 5‐ARI dual therapy was associated with reduced levels of fPSA, [−2]proPSA, and PHI. Therapy combining alpha‐blockers and antimuscarinic agents did not significantly influence biomarker levels apart from an increase in a Maackia amurensis lectin‐recognized glycan originating in fPSA.

Conclusion

BPH pharmacotherapy notably affects prostate cancer biomarkers. Recognizing the impact of pharmacotherapy is crucial for achieving an accurate diagnosis of prostate cancer and for planning treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Prostate-Specific AntigenProstatic HyperplasiaMuscarinic AntagonistsHumansMaleAgedMiddle AgedGlycosylationAdrenergic alpha-Antagonists5-alpha Reductase InhibitorsAged, 80 and overProstateProstatic Neoplasms

Stichwörter der Autor:innen

5‐alpha reductase inhibitorsPSAalpha‐blockersantimuscarinic agentsbenign prostate hyperplasiaprostate cancer

Substanzen

Prostate-Specific AntigenMuscarinic AntagonistsAdrenergic alpha-Antagonists5-alpha Reductase Inhibitors

Autor:innen und Institutionen

  • Department of Pharmacology and Toxicology, Faculty of Medicine in Pilsen, Charles University, Pilsen, 323 00, Czech Republic.
  • Department of Immunochemistry Diagnostics, University Hospital and Faculty of Medicine in Pilsen, Charles University, Pilsen, 323 00, Czech Republic.
  • Glycanostics, Ltd., Kudlakova 7, Bratislava 841 01, Slovak Republic.
  • Institute of Chemistry, Slovak Academy of Sciences, Dubravska cesta 9, 845 38, Bratislava, Slovak Republic.

ORCID-Profile: Michal Jirásko, Roman Viták, Andrea Pinkeová

Förderung

  • "COOPERATIO" Program, research area Pharmaceutical Sciences
  • project BBMRI. cz, reg. no. LM2023033
  • Faculty Hospital in Pilsen-FNPl, 00669806

Zitieren

APA

Jirásko, M., Viták, R., Pecen, L., Pinkeová, A., Tkáč, J., Bertók, T., Bergman, N., & Kučera, R. (2025). Serum levels of prostate specific antigen, free PSA, [−2]proPSA, fPSA/tPSA ratio, Prostate Health Index, and glycosylation patterns of free PSA in patients with benign prostatic hyperplasia pharmacotherapy. The Prostate. https://doi.org/10.1002/pros.24801

Vancouver

Jirásko M, Viták R, Pecen L, Pinkeová A, Tkáč J, Bertók T, et al. Serum levels of prostate specific antigen, free PSA, [−2]proPSA, fPSA/tPSA ratio, Prostate Health Index, and glycosylation patterns of free PSA in patients with benign prostatic hyperplasia pharmacotherapy. The Prostate. 2025. doi:10.1002/pros.24801

BibTeX
@article{Jirsko2025,
  author = {Jirásko, Michal and Viták, Roman and Pecen, Ladislav and Pinkeová, Andrea and Tkáč, Jan and Bertók, Tomáš and Bergman, Natalie and Kučera, Radek},
  title = {Serum levels of prostate specific antigen, free PSA, [−2]proPSA, fPSA/tPSA ratio, Prostate Health Index, and glycosylation patterns of free PSA in patients with benign prostatic hyperplasia pharmacotherapy},
  journal = {The Prostate},
  year = {2025},
  doi = {10.1002/pros.24801}
}
Kostenlos starten →